Create Free Account

By creating account you will get access to hot stocks & personalised emails

Nova Eye Medical Ltd

Healthcare AU EYE

0.15AUD
-0.01(6.25%)

Last update at 2024-11-13T05:10:00Z

Day Range

0.150.16
LowHigh

52 Week Range

0.120.33
LowHigh

Fundamentals

  • Previous Close 0.16
  • Market Cap34.36M
  • Volume345024
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-5.97900M
  • Revenue TTM23.32M
  • Revenue Per Share TTM0.11
  • Gross Profit TTM 14.39M
  • Diluted EPS TTM-0.04

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -17.00200M -8.24600M -5.25000M -7.24900M -5.65600M
Minority interest - - - - -
Net income -15.29300M -7.49600M -4.35600M 35.65M -5.77300M
Selling general administrative 11.26M 10.04M 7.87M 9.95M 32.47M
Selling and marketing expenses 3.20M 1.77M 0.73M 0.67M 2.87M
Gross profit 14.61M 11.34M 11.15M 9.75M 50.80M
Reconciled depreciation 2.30M 1.81M 1.51M 1.44M 2.14M
Ebit -5.73500M -9.69900M -5.24500M -7.19100M -5.04700M
Ebitda -3.43800M -7.88800M -3.73000M -5.75300M -1.03600M
Depreciation and amortization 2.30M 1.81M 1.51M 1.44M 4.01M
Non operating income net other - - - - -
Operating income -11.77900M -9.69900M -4.96500M -7.12300M -5.04700M
Other operating expenses -28.81400M -16.58700M -14.32900M -14.01000M 87.99M
Interest expense - 0.03M 0.00500M 0.06M 0.41M
Tax provision -1.70900M -0.75000M -0.89400M 3.08M -1.30200M
Interest income 0.08M 0.03M 0.55M 0.20M 0.04M
Net interest income 0.05M -0.03000M 0.17M -0.05800M -0.23700M
Extraordinary items - - 0.00000M 45.98M 0.89M
Non recurring - - - - -
Other items - - - - -
Income tax expense -1.70900M -0.75000M -0.89400M 3.08M 0.12M
Total revenue 17.24M 13.63M 13.39M 12.77M 81.64M
Total operating expenses 26.39M 21.04M 16.32M 16.92M 57.15M
Cost of revenue 2.63M 2.29M 2.24M 3.02M 30.84M
Total other income expense net -5.27200M 1.48M -0.25400M -0.06300M -0.60900M
Discontinued operations - - - 45.98M 0.89M
Net income from continuing ops -15.29300M -7.49600M -4.35600M -10.32700M -5.77300M
Net income applicable to common shares -15.29300M -7.49600M -4.35600M 35.65M -5.77300M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 29.88M 30.36M 36.62M 41.99M 116.74M
Intangible assets - 8.45M 7.17M 3.44M 3.34M
Earning assets - - - - -
Other current assets 0.23M 1.15M 1.85M 1.60M 0.49M
Total liab 8.55M 7.17M 6.23M 6.66M 16.16M
Total stockholder equity 21.33M 23.19M 30.40M 35.34M 100.59M
Deferred long term liab - 4.87M 10.85M 8.65M 7.54M
Other current liab 1.64M 1.96M 1.46M 2.68M 10.53M
Common stock 52.71M 45.17M 37.44M 36.68M 78.31M
Capital stock - 45.17M 37.44M 36.68M 78.31M
Retained earnings -30.68700M -21.89700M -6.60400M 0.89M 24.63M
Other liab - - 0.97M 0.21M 0.36M
Good will - - - - -
Other assets - 4.94M 10.92M 8.72M 7.58M
Cash 6.15M 7.42M 8.00M 17.80M 95.65M
Cash and equivalents - 7.42M 8.00M 17.80M 95.65M
Total current liabilities 5.68M 6.27M 3.86M 4.69M 14.36M
Current deferred revenue - -0.63900M -0.54400M -1.93800M -1.90900M
Net debt -2.80200M -5.88800M -6.05700M -14.10300M -92.30700M
Short term debt 0.48M 0.64M 0.54M 1.94M 1.91M
Short long term debt - - - 1.42M 1.55M
Short long term debt total 3.35M 1.53M 1.94M 3.70M 3.34M
Other stockholder equity - -23.27800M -30.83600M -37.57000M -102.94500M
Property plant equipment - 2.36M 2.94M 3.51M 2.91M
Total current assets 14.75M 14.60M 15.59M 26.33M 102.91M
Long term investments - - - - -
Net tangible assets - 14.74M 23.22M 31.89M 97.25M
Short term investments - - - - -
Net receivables 4.08M 2.22M 2.20M 4.02M 3.83M
Long term debt - 0.89M - - -
Inventory 4.28M 3.81M 3.54M 2.90M 2.93M
Accounts payable 3.57M 4.31M 2.41M 2.00M 3.83M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.69300M -0.08700M -0.43900M -2.23500M -2.35900M
Additional paid in capital - - - - -
Common stock total equity - - - - 78.31M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 11.16M 0.07M 0.07M 0.06M 0.05M
Deferred long term asset charges - - - - -
Non current assets total 15.13M 15.76M 21.04M 15.67M 13.84M
Capital lease obligations - 1.53M 1.94M 2.28M 1.79M
Long term debt total - 0.89M 1.40M 1.76M 1.43M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.69700M -4.54100M -2.98000M -0.09700M -0.09700M
Change to liabilities -0.43300M 0.54M -1.82300M -10.96200M 1.08M
Total cashflows from investing activities -0.69700M -4.54100M -2.98000M 88.31M -3.49100M
Net borrowings -0.65300M -0.40200M -0.58200M -13.28900M -0.10900M
Total cash from financing activities 6.82M -0.40200M -61.61200M -13.28900M -0.10900M
Change to operating activities 0.21M 0.00600M 1.43M -1.67900M 0.38M
Net income -15.29300M -7.49600M -4.35600M 35.65M -5.77300M
Change in cash -0.58100M -9.80100M -77.84800M 80.47M -7.88400M
Begin period cash flow 8.00M 17.80M 95.65M 15.18M 23.07M
End period cash flow 7.42M 8.00M 17.80M 95.65M 15.18M
Total cash from operating activities -6.82400M -4.71800M -13.14400M 5.40M -4.20700M
Issuance of capital stock 7.47M - - - -
Depreciation 2.30M 1.81M 1.51M 2.34M 4.01M
Other cashflows from investing activities -0.13000M -0.96500M 0.24M 89.92M 0.17M
Dividends paid - 0.00000M -19.38600M 19.39M 19.39M
Change to inventory -0.26600M -0.63900M 0.03M 3.78M -3.47100M
Change to account receivables -0.00200M 1.82M -1.61600M 14.39M -0.82900M
Sale purchase of stock 7.47M 0.00000M -41.64400M -41.64400M 0.00000M
Other cashflows from financing activities -0.65300M -0.40200M -0.58200M -0.98000M 0.69M
Change to netincome 5.98M -1.42200M -0.66500M -50.79100M 3.09M
Capital expenditures 0.80M 5.59M 2.23M 1.66M 3.67M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.26800M 1.18M -1.58300M 18.17M 0.06M
Stock based compensation 0.18M 0.20M - - -
Other non cash items 6.17M 0.97M -8.72000M -50.76700M 3.63M
Free cash flow -7.62400M -10.30900M -15.37200M 3.74M -7.87200M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
EYE
Nova Eye Medical Ltd		 -0.01 6.25% 0.15 - - 1.47 1.56 1.30 -3.9647
COH
Cochlear Ltd		 -2.48 0.83% 296.93 53.21 47.17 8.48 10.35 8.40 32.43
PNV
Polynovo Ltd		 - -% 2.06 208.00 135.14 13.92 19.54 13.36 340.64
AVH
Avita Therapeutics Inc		 0.14 3.80% 3.82 - - 8.76 12.74 5.31 -10.0538
EBR
Ebr Systems Inc CDR		 0.01 1.48% 1.03 - - - 21.41 - -3.6785

Reports Covered

Stock Research & News

View All

Profile

Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. The company offers iTrack, a glaucoma surgical device to reduce intraocular pressure in adult patients with open-angle glaucoma; iTrack Advance, a canaloplasty microcatheter which offers malleability and manoeuvrability than common nylon alternatives; Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma; and 2RT, a proprietary laser technology to treat patients in early/intermediate age-related macular degeneration. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020. Nova Eye Medical Limited was incorporated in 1970 and is headquartered in Kent Town, Australia.

Nova Eye Medical Ltd

107 Rundle Street, Kent Town, SA, Australia, 5067

Key Executives

Name Title Year Born
Mr. Victor Previn B.E., B.Eng Founder & Exec. Chairman 1958
Mr. Thomas H. Spurling AM, BSc (Hons), FRACI, FTSE, Ph.D. MD & Exec. Director 1962
Liam Cook Chief Financial Officer NA
Mr. Keith Byrne VP of Global Operations NA
Mark Flynn Investor Relations NA
Ms. Kate Hunt Head of Marketing NA
Dr. David Lubeck M.D. Chief Medical Officer NA
Mr. Bill Swaim Pres of Laserex IS Ellex (USA) NA
Mr. Joaquin V. Wolff Pres of Ellex iTrack 1958
Ms. Kimberley Menzies Group Financial Controller & Global Fin. Mang. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.